SALT LAKE CITY, May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announced financial results for the quarter ended March 31, 2022 and provided a corporate update.
Program Highlights
- TLANDO™ was approved and granted Market Exclusivity by the U.S. Food and Drug Administration ("FDA") for hypogonadism and our licensee expects commercial launch in second quarter of 2022
- Lipocine is currently enrolling subjects in a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148 for the management of cirrhosis, with enrollment in the study expected to be complete by the end of the third quarter of 2022
- Lipocine has requested an End of Phase 2 meeting to discuss the Phase 3 study and confirmatory trial design for LPCN 1144 in non-cirrhotic non-alcoholic steatohepatitis ("NASH")
- An open label extension ("OLE") study in non-cirrhotic NASH has been completed and topline results are expected in May 2022
Board Appointments
The company appointed Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors in April 2022
First Quarter Ended March 31, 2022 Financial Results
Lipocine reported a net loss of $3.5 million or ($0.04 per diluted share), for the quarter ended March 31, 2022, compared with a net loss of $3.4 million, or ($0.04) per diluted share, in the quarter ended March 31, 2021.
Research and development expenses were $1.9 million for the quarter ended March 31, 2022, compared with $1.6 million for the quarter ended March 31, 2021. The increase in research and development expenses for the quarter ended March 31, 2022, was a result of increases in contract research organization expenses related to the ongoing Phase 2 clinical study for LPCN 1148, PK and food effect studies for LPCN 1107 and LPCN 1154, manufacturing scale up expenses for LPCN 1111, and an increase in personnel and other R&D expenses. These increases were offset by a decrease in contract research organization expense and outside consulting costs related to the LPCN 1144 LiFT Phase 2 clinical study and a decrease in costs related to TLANDO.
General and administrative expenses were $1.2 million for the quarter ended March 31, 2022, compared with $1.5 million for the quarter ended March 31, 2021. The decrease in general and administrative expenses for the quarter ended March 31, 2022, was primarily due to decreases in legal costs, personnel costs and other general and administrative costs. These decreases were offset by increases in professional fees related to various consulting and proxy solicitation services as well as an increase in corporate insurance expenses.
As of March 31, 2022, the company had $42.0 million of unrestricted cash, cash equivalents and marketable investment securities compared to $46.6 million as of December 31, 2021.
About Lipocine
Lipocine Inc. is a biopharmaceutical company focused on neuroendocrine and metabolic disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: LPCN 1148, LPCN 1144, LPCN 1111, LPCN 1107 and oral neuroactive steroids including LPCN 1154 and LPCN 2101. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the management of symptoms associated with liver cirrhosis. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating potential utility in the treatment of non-cirrhotic NASH. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once or twice daily, LPCN 1111 met primary and secondary endpoints. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. Neuroactive steroids are currently being evaluated including LPCN 1154 for the potential treatment of postpartum depression and LPCN 2101 for the potential treatment of epilepsy. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
*TLANDO® is a registered trademark assigned to Antares Pharma.
LIPOCINE INC. AND SUBSIDIARIES | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
March 31, | December 31, | |||||||
2022 | 2021 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ 5,733,231 | $ 2,950,552 | ||||||
Marketable investment securities | 36,266,299 | 41,667,405 | ||||||
Accrued interest income | 120,094 | 247,253 | ||||||
Prepaid and other current assets | 1,377,925 | 1,514,465 | ||||||
Total current assets | 43,497,549 | 46,379,675 | ||||||
Marketable investment securities | - | 2,021,800 | ||||||
Contract asset | 4,050,000 | 4,050,000 | ||||||
Property and equipment, net of accumulated depreciation | ||||||||
of $1,145,796 and $1,144,077, respectively | 32,289 | 7,211 | ||||||
Other assets | 23,753 | 23,753 | ||||||
Total assets | $ 47,603,591 | $ 52,482,439 | ||||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ 469,887 | $ 1,289,342 | ||||||
Accrued expenses | 567,901 | 1,016,458 | ||||||
Debt - current portion | 1,482,165 | 2,310,825 | ||||||
Litigation settlement liability - current portion | 1,000,000 | 1,000,000 | ||||||
Total current liabilities | 3,519,953 | 5,616,625 | ||||||
Warrant liability | 1,173,785 | 795,796 | ||||||
Litigation settlement liability - non-current portion | 500,000 | 500,000 | ||||||
Total liabilities | 5,193,738 | 6,912,421 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, par value $0.0001 per share, 10,000,000 | ||||||||
shares authorized; zero issued and outstanding | - | - | ||||||
Common stock, par value $0.0001 per share, 100,000,000 | ||||||||
shares authorized; 88,504,634 and 88,296,360 issued | ||||||||
and 88,498,924 and 88,290,650 outstanding | 8,850 | 8,829 | ||||||
Additional paid-in capital | 218,663,319 | 218,286,324 | ||||||
Treasury stock at cost, 5,710 shares | (40,712) | (40,712) | ||||||
Accumulated other comprehensive loss | (67,416) | (18,016) | ||||||
Accumulated deficit | (176,154,188) | (172,666,407) | ||||||
Total stockholders' equity | 42,409,853 | 45,570,018 | ||||||
Total liabilities and stockholders' equity | $ 47,603,591 | $ 52,482,439 | ||||||
LIPOCINE INC. AND SUBSIDIARIES | |||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss | |||||||||
(Unaudited) | |||||||||
Three Months Ended March 31, | |||||||||
2022 | 2021 | ||||||||
Revenues | $ - | $ - | |||||||
Operating expenses: | |||||||||
Research and development | 1,887,953 | 1,580,540 | |||||||
General and administrative | 1,243,687 | 1,533,953 | |||||||
Total operating expenses | 3,131,640 | 3,114,493 | |||||||
Operating loss | (3,131,640) | (3,114,493) | |||||||
Other income (expense): | |||||||||
Interest and investment income | 41,576 | 10,649 | |||||||
Interest expense | (19,529) | (68,973) | |||||||
Unrealized loss on warrant liability | (377,988) | (195,065) | |||||||
Total other expense, net | (355,941) | (253,389) | |||||||
Loss before income tax expense | (3,487,581) | (3,367,882) | |||||||
Income tax expense | (200) | (200) | |||||||
Net loss | $ (3,487,781) | $ (3,368,082) | |||||||
Basic loss per share attributable to common stock | $ (0.04) | $ (0.04) | |||||||
Weighted average common shares outstanding, basic | 88,309,628 | 81,881,392 | |||||||
Diluted loss per share attributable to common stock | $ (0.04) | $ (0.04) | |||||||
Weighted average common shares outstanding, diluted | 88,309,628 | 81,881,392 | |||||||
Comprehensive loss: | |||||||||
Net loss | $ (3,487,781) | $ (3,368,082) | |||||||
Net unrealized loss on available-for-sale securities | (49,400) | (22,459) | |||||||
Comprehensive loss | $ (3,537,181) | $ (3,390,541) | |||||||
SOURCE Lipocine Inc.
